Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 272 entries
View as:

Efficacy Study of Dysport® in the Treatment of Anal Fissure.

Phase: N/A Priority: Normal
NCT ID: NCT00210444 Org: User:
Start: 06/30/03 End: 12/31/06 Due: 12/31/07

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

Phase: N/A Priority: Normal
NCT ID: NCT00247559 Org: User:
Start: 05/31/04 End: 04/08/05 Due: 04/08/06

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT02353871 Org: User:
Start: 01/31/15 End: 08/31/15 Due: 08/31/16

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Phase: N/A Priority: Normal
NCT ID: NCT04752774 Org: User:
Start: 04/29/21 End: 10/30/27 Due: 10/30/28

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Phase: N/A Priority: Normal
NCT ID: NCT00903110 Org: User:
Start: 12/09/08 End: 12/31/27 Due: 12/31/28

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

Phase: N/A Priority: Normal
NCT ID: NCT01560858 Org: User:
Start: 04/30/12 End: 05/31/13 Due: 05/31/14

Spasticity and Treatment Satisfaction Among Stroke Survivors

Phase: N/A Priority: Normal
NCT ID: NCT03995524 Org: User:
Start: 07/20/19 End: 05/12/20 Due: 05/12/21

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)

Phase: N/A Priority: Normal
NCT ID: NCT01840475 Org: User:
Start: 03/31/13 End: 02/06/18 Due: 02/06/19

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

Phase: N/A Priority: Normal
NCT ID: NCT04821089 Org: User:
Start: 04/06/21 End: 03/05/27 Due: 03/05/28

Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)

Phase: N/A Priority: Normal
NCT ID: NCT04106349 Org: User:
Start: 03/03/20 End: 06/30/26 Due: 06/30/27

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

Phase: N/A Priority: Normal
NCT ID: NCT03647878 Org: User:
Start: 09/24/18 End: 09/30/27 Due: 09/30/28

A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults

Phase: N/A Priority: Normal
NCT ID: NCT05361434 Org: User:
Start: 09/26/22 End: 11/30/26 Due: 11/30/27

A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.

Phase: N/A Priority: Normal
NCT ID: NCT04396704 Org: User:
Start: 01/11/21 End: 03/30/21 Due: 03/30/22

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00383708 Org: User:
Start: 10/31/06 End: 10/31/08 Due: 10/31/09

Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm

Phase: N/A Priority: Normal
NCT ID: NCT00216411 Org: User:
Start: 11/30/04 End: 07/20/06 Due: 07/20/07

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

Phase: N/A Priority: Normal
NCT ID: NCT00686348 Org: User:
Start: 05/31/08 End: 11/30/15 Due: 11/30/16

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00288522 Org: User:
Start: 01/31/06 End: 04/30/07 Due: 04/30/08

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

Phase: N/A Priority: Normal
NCT ID: NCT00824512 Org: User:
Start: 06/30/08 End: 10/31/11 Due: 10/31/12

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Phase: N/A Priority: Normal
NCT ID: NCT04736602 Org: User:
Start: 03/27/21 End: 09/03/22 Due: 09/03/23

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT02698410 Org: User:
Start: 07/31/16 End: 06/18/19 Due: 06/18/20

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

Phase: N/A Priority: Normal
NCT ID: NCT03045302 Org: User:
Start: 01/26/17 End: 06/02/17 Due: 06/02/18

Dysport® Adult Upper Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT01313299 Org: User:
Start: 08/31/11 End: 09/30/13 Due: 09/30/14

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Phase: N/A Priority: Normal
NCT ID: NCT02592707 Org: User:
Start: 03/06/17 End: 02/22/22 Due: 02/22/23

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Phase: N/A Priority: Normal
NCT ID: NCT02660359 Org: User:
Start: 07/08/16 End: 07/04/19 Due: 07/04/20

A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06850038 Org: User:
Start: 04/22/25 End: 11/30/29 Due: 11/30/30